Mendus AB (publ) (STO:IMMU)
Sweden · Delayed Price · Currency is SEK | Market Cap | 348.14M -4.4% |
| Revenue (ttm) | n/a |
| Net Income | -102.49M |
| EPS | -1.60 |
| Shares Out | 64.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,840 |
| Open | 5.500 |
| Previous Close | 5.500 |
| Day's Range | 5.010 - 5.560 |
| 52-Week Range | 3.860 - 8.490 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 33.95 (+525.23%) |
| Earnings Date | Nov 11, 2026 |
About Mendus AB
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. T... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for IMMU stock is "Buy." The 12-month stock price target is kr 33.95, which is an increase of 525.23% from the latest price.
News
Mendus AB Earnings Call Transcript: Q2 2026
Clinical development advanced with the ADVANCE II trial reaching five-year survival and the CADENCE trial confirming safety and enrollment milestones. Financial discipline reduced costs and extended cash runway into Q1 2027. Multiple clinical readouts and U.S. expansion are planned, contingent on further financing.
Mendus AB Quarterly report: Q2 2026
Mendus AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
Mendus AB Slides: Corporate presentation
Mendus AB has posted slides in relation to its latest quarterly earnings report, which was published on August 20, 2026.
Mendus AB Earnings Call Transcript: Q1 2026
Clinical programs in AML and CML advanced, with reduced costs and a strengthened cash position. Recruitment in key trials is ongoing, with interim results expected mid-year and a focus on broadening patient eligibility.
Mendus AB Quarterly report: Q1 2026
Mendus AB has published its Q1 2026 quarterly earnings report on May 8, 2026.
Mendus AB Slides: Q1 2026
Mendus AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Mendus AB Slides: Corporate presentation
Mendus AB has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Mendus AB Earnings Call Transcript: Q4 2025
Positive phase II data in AML and ovarian cancer support broad positioning of vididencel, with new CML trials planned for 2026. Financing secured extends runway into 2027, and strategic focus shifts to align with evolving AML and CML treatment landscapes.
Mendus AB Quarterly report: Q4 2025
Mendus AB has published its Q4 2025 quarterly earnings report on February 11, 2026.
Mendus AB Slides: Q4 2025
Mendus AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 11, 2026.
Mendus AB Annual report: Q4 2025
Mendus AB has published its Q4 2025 annual report on February 11, 2026.
Mendus AB Earnings Call Transcript: Q3 2025
Positive long-term survival data in AML supports broader clinical development, with key trials in AML, CML, and ovarian cancer advancing. Cash runway extends into early 2026, with staff reductions offsetting higher trial costs.
Mendus AB Quarterly report: Q3 2025
Mendus AB has published its Q3 2025 quarterly earnings report on November 13, 2025.
Mendus AB Slides: Q3 2025
Mendus AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.